Why the study?
In contrast with coronary artery disease, the use of dual antiplatelet therapy for secondary prevention in patients with acute cerebral ischemia remained under debate.
Does dual antiplatelet therapy improve secondary prevention compared to single antiplatelet therapy in patients with minor acute ischemic stroke or high-risk TIA?
Does dual antiplatelet therapy improve secondary prevention compared to single antiplatelet therapy in patients with minor acute ischemic stroke or high-risk TIA?
Short-term dual antiplatelet therapy is effective for early secondary prevention in patients with minor acute ischemic stroke or high-risk TIA, though optimal duration and patient selection require further individualization.
No takes yet. Share an insight, caveat, or question.
DAPT for acute cerebral ischemia remains debated; leaves open optimal regimen, timing, and duration in secondary prevention.
Kargiotis et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: